GeneticsLandmark
Whole-genome sequencing of Lp(a) in European and African ancestries (Zekavat et al., Nat Commun 2018)
Original title: Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries
Deep-coverage whole-genome sequences of 8,392 people of European and African ancestry mapped the single-nucleotide and copy-number determinants of Lp(a): the genetic architecture differs between the two ancestries, rare non-coding variant signals are largely explained by LPA kringle IV type 2 copy number, and LPA risk genotypes conferred greater relative risk of incident ASCVD than the measured Lp(a) itself, with associations with subclinical atherosclerosis in African Americans. Foundational for the ancestry debate and for genotype-based risk scores.
Original abstract
Lipoprotein(a), Lp(a), is a modified low-density lipoprotein particle that contains apolipoprotein(a), encoded by LPA, and is a highly heritable, causal risk factor for cardiovascular diseases that varies in concentrations across ancestries. Here, we use deep-coverage whole genome sequencing in 8392 individuals of European and African ancestry to discover and interpret both single-nucleotide variants and copy number (CN) variation associated with Lp(a). We observe that genetic determinants between Europeans and Africans have several unique determinants. The common variant rs12740374 associated with Lp(a) cholesterol is an eQTL for SORT1 and independent of LDL cholesterol. Observed associations of aggregates of rare non-coding variants are largely explained by LPA structural variation, namely the LPA kringle IV 2 (KIV2)-CN. Finally, we find that LPA risk genotypes confer greater relative risk for incident atherosclerotic cardiovascular diseases compared to directly measured Lp(a), and are significantly associated with measures of subclinical atherosclerosis in African Americans.
ancestryepidemiologygeneticstesting
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.